Search
Close this search box.

Taking stock of the frenzied push into autoimmune disease

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Good morning! This is a magical time of the year in Boston, with trees in full bloom. I want to hear from you! Send me email at BiotechScorecard@statnews.com.

advertisement

Where art thou, lupus patients?

This week, Cullinan Oncology, now known as Cullinan Therapeutics, became the latest company to pivot from cancer to autoimmune disease. It joins Crispr Therapeutics, Cabaletta Bio, Nkarta, Caribou Biosciences, Allogene Therapeutics, Gracell (AstraZeneca), Bristol Myers Squibb, Fate Therapeutics, Eliem Therapeutics/Tenet Medicines, and Century Therapeutics/Clade Therapeutics in making the same shift, either partially or completely.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe